ReviewHepatology (Baltimore, Md.)2014
Engineering liver.
Review in Hepatology (Baltimore, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Semi-synthetic fibrous fibrin composites promote 3D microvascular assembly, survival, and host integration of endothelial cells without mesenchymal cell support.Bioactive materials · 2025Article
- Reproducibility and Robustness of a Liver Microphysiological System PhysioMimix LC12 under Varying Culture Conditions and Cell Type Combinations.Bioengineering (Basel, Switzerland) · 2023Article
- Current and Novel Therapeutical Approaches of Classical Homocystinuria in Childhood With Special Focus on Enzyme Replacement Therapy, Liver-Directed Therapy and Gene Therapy.Journal of clinical medicine research · 2023Review
- Prediction of hepatic drug clearance with a human microfluidic four-cell liver acinus microphysiology system.Toxicology · 2021Article
- Integrative microphysiological tissue systems of cancer metastasis to the liver.Seminars in cancer biology · 2021Review
- Analysis of reproducibility and robustness of a human microfluidic four-cell liver acinus microphysiology system (LAMPS).Toxicology · 2021Article
- Integrated Isogenic Human Induced Pluripotent Stem Cell-Based Liver and Heart Microphysiological Systems Predict Unsafe Drug-Drug Interaction.Frontiers in pharmacology · 2021Article
- Liver Bioengineering: Promise, Pitfalls, and Hurdles to Overcome.Current transplantation reports · 2019Article
- Directing the growth and alignment of biliary epithelium within extracellular matrix hydrogels.Acta biomaterialia · 2019Article
- Complex bile duct network formation within liver decellularized extracellular matrix hydrogels.Scientific reports · 2018Article
- 3D-printed gelatin scaffolds of differing pore geometry modulate hepatocyte function and gene expression.Acta biomaterialia · 2018Article
- Liver 'organ on a chip'.Experimental cell research · 2018Review
- Microphysiological Systems to Assess Nonclinical Toxicity.Current protocols in toxicology · 2017Article
- A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms.Stem cell reviews and reports · 2017Review
- 3D Proximal Tubule Tissues Recapitulate Key Aspects of Renal Physiology to Enable Nephrotoxicity Testing.Frontiers in physiology · 2017Article
- Liver metastases: Microenvironments and ex-vivo models.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- The Microphysiology Systems Database for Analyzing and Modeling Compound Interactions with Human and Animal Organ Models.Applied in vitro toxicology · 2016Article
- A human liver microphysiology platform for investigating physiology, drug safety, and disease models.Experimental biology and medicine (Maywood, N.J.) · 2016Article
- Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact.Digestive diseases and sciences · 2015Review
- Mind the gap-deficits in our knowledge of aspects impacting the bioavailability of phytochemicals and their metabolites--a position paper focusing on carotenoids and polyphenols.Molecular nutrition & food research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Interest in "engineering liver" arises from multiple communities: therapeutic replacement; mechanistic models of human processes; and drug safety and efficacy studies. An explosion of micro- and nanofabrication, biomaterials, microfluidic, and other technologies potentially affords unprecedented opportunity to create microphysiological models of the human liver, but engineering design principles for how to deploy these tools effectively toward specific applications, including how to define the essential constraints of any given application (available sources of cells, acceptable cost, and user-friendliness), are still emerging. Arguably less appreciated is the parallel growth in computational systems biology approaches toward these same problems-particularly in parsing complex disease processes from clinical material, building models of response networks, and in how to interpret the growing compendium of data on drug efficacy and toxicology in patient populations. Here, we provide insight into how the complementary paths of engineering liver-experimental and computational-are beginning to interplay toward greater illumination of human disease states and technologies for drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.